Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Monday, February 14, 2022
Eli Lilly and Company announced an agreement with the U.S. government to supply up to 600,000 doses of investigational drug bebtelovimab for at least $720 million.
read more
Monday, February 14, 2022
The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 ...
read more
Tuesday, February 08, 2022
Merck and Ridgeback Biotherapeutics announced that a total of approximately 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been provided to the U.S. ...
read more
Tuesday, February 08, 2022
New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for ...
read more
Tuesday, February 08, 2022
Seqirus, a business of CSL Limited, announced an investment in a new Research and Development (R&D) facility located in Waltham, Mass. The new facility will support the company's growing R&D portfolio...
read more
Wednesday, February 02, 2022
The U.S. Food and Drug Administration approved a second COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the ...
read more
Wednesday, February 02, 2022
Novavax, Inc. and Israel's Ministry of Health announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ ...
read more
Wednesday, February 02, 2022
Pfizer Inc. and BioNTech SE announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission seeking to amend the Emergency Use ...
read more
Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an investigational oral antiviral COVID-19 medicine, was active against the SARS-CoV-2 ...
read more
Wednesday, January 26, 2022
In light of the most recent information and data available, the FDA revised the authorizations for two monoclonal antibody treatments – bamlanivimab and etesevimab (administered together) and REGEN-...
read more
Tuesday, January 25, 2022
Pfizer Inc. and BioNTech SE announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine candidate in healthy adults 18 through 55 ...
read more
Thursday, January 20, 2022
Valneva SE announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the ...
read more
Wednesday, January 19, 2022
Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the United Nations Children’s Fund (UNICEF) to facilitate broad global access for molnupiravir, an ...
read more
Wednesday, January 05, 2022
Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the Pfizer-BioNTech COVID-19 Vaccine to ...
read more
Tuesday, January 04, 2022
BiondVax Pharmaceuticals Ltd. has announced the signing of definitive agreements with the Max Planck Society (MPG), the parent organization of the Max Planck Institute of Biophysical Chemistry, and ...
read more